Thousands of Americans Live With This Rare Condition—New Drug May Give Hope
Summary
A new experimental drug called tanruprubart is showing promise as the first targeted treatment for Guillain-Barré syndrome (GBS), a rare nerve disease where the immune system attacks nerves. Early trial results show a single infusion of the drug can quickly improve muscle strength and help patients recover faster than current treatments.Key Facts
- Guillain-Barré syndrome (GBS) affects about 150,000 people worldwide each year and can cause paralysis.
- There is currently no FDA-approved treatment for GBS anywhere in the world.
- Tanruprubart works by blocking C1q, a molecule that triggers the immune system to attack nerve cells.
- The drug is given as a single intravenous infusion and aims to stop nerve damage early.
- In a Phase 3 trial, patients treated with tanruprubart showed a 10-point improvement in muscle strength within the first week compared to standard treatments.
- Patients receiving tanruprubart were about three times more likely to have better health outcomes at 4, 8, and 26 weeks.
- Benefits included improved strength, mobility, balance, and faster return to daily activities.
- Early treatment with tanruprubart led to greater benefits by preventing irreversible nerve damage.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
